Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the online calls and meetings and deadlines that are piling up. Meanwhile, here is the latest grab of items of interest to help you along. Hope you conquer the world today, and do stay in touch. …
A U.S. Food and Drug Administration expert panel voted overwhelmingly to recommend the agency issue an emergency use authorization for the Novavax Covid-19 vaccine — a long-awaited win for a company that has struggled to reach this point, STAT writes. The Vaccines and Related Biological Products Advisory Committee voted 21-to-0 to recommend the vaccine receive an EUA, with a single abstention. The strong vote belied the tenor of much of the discussion, which started with one member of the committee, Eric Rubin, editor of the New England Journal of Medicine, questioning whether additional EUAs are needed when three vaccines are already in use in the country.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
